Youwen Zhu

发表

Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater.

D. Carbone, Liangfang Shen, Jin Huang, 2019, Lung cancer.

Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S.

Liangfang Shen, S. Zeng, Longjiang She, 2020 .

Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis

Yangying Zhou, Dong Ding, Youwen Zhu, 2022, Advances in Therapy.

Chemo-Immunotherapy Regimes for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis

X. Tan, Dong Ding, Youwen Zhu, 2022, Frontiers in Pharmacology.

Vascular Endothelial Growth Factor Receptor Inhibitors in Chinese Patients With Advanced Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Network Meta-Analysis and Cost-Effectiveness Analysis

Youwen Zhu, Libo Peng, Kun Liu, 2022, Frontiers in Endocrinology.

Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: A United States-based cost-effectiveness analysis.

Y. Zhang, Yangying Zhou, Youwen Zhu, 2022, Gynecologic oncology.

E cacy and Safety of Immuno-based Therapy Versus Standard of Care in Extensive-stage Small- Cell Lung Cancer: An Updated Meta-analysis of Randomized Clinical Trials

Hong, Zhu, You-Shan Dai, 2022 .

Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer.

Jin Huang, Jin Liu, Huabin Hu, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Trastuzumab deruxtecan versus chemotherapy for patients with HER2-low advanced breast cancer: A US-based cost-effectiveness analysis

Youwen Zhu, Xiaolu Zhu, Kun Liu, 2022, Frontiers in Pharmacology.

Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis

Min Wang, Youwen Zhu, Libo Peng, 2022, Breast.

Hong Zhu, Youwen Zhu, Kun Liu, 2022, Cancer.

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer

D. Carbone, Jin Huang, Huabin Hu, 2020, Frontiers in Oncology.

First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis

Jin Huang, Huabin Hu, Mengting Liao, 2021, Cost Effectiveness and Resource Allocation.

Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA

Jin Huang, Huabin Hu, Youwen Zhu, 2021, Advances in Therapy.

First-Line Lenvatinib Plus Pembrolizumab or Everolimus versus Sunitinib for Advanced Renal Cell Carcinoma: A United States-Based Cost-Effectiveness Analysis.

Youwen Zhu, Libo Peng, Kun Liu, 2022, Clinical genitourinary cancer.

Cost-effectiveness of pembrolizumab plus axitinib versus sunitinib as first-line therapy in advanced renal-cell carcinoma in the United States.

Liangfang Shen, Jin Huang, Huabin Hu, 2020, The oncologist.

Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer

Jin Huang, Huabin Hu, S. Zeng, 2020, Advances in Therapy.

Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis

Youwen Zhu, Kun Liu, Qun Qin, 2023, Frontiers in Immunology.

Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: A network meta-analysis and cost-effectiveness analysis

Youwen Zhu, Kun Liu, Hong Zhu, 2023, Frontiers in Immunology.

Cemiplimab as Second-Line Therapy for Patients with Recurrent Cervical Cancer: A United States-based Cost-effectiveness Analysis

Hong Zhu, Youwen Zhu, Kun Liu, 2023, Advances in Therapy.

First-Line Pembrolizumab Plus Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A United States-Based Cost-Effectiveness Analysis

Jin Huang, Huabin Hu, Mengting Liao, 2021 .

First-line Immuno-chemotherapy for extensive-stage small-cell lung cancer: A network meta-analysis and cost-effectiveness analysis

Youwen Zhu, Libo Peng, Manting Zeng, 2023, Frontiers in Public Health.

Olaparib plus bevacizumab as a first-line maintenance treatment for patients with advanced ovarian cancer by molecular status: an updated PAOLA-1 based cost-effectiveness analysis.

Hong Zhu, Youwen Zhu, Kun Liu, 2023, Journal of gynecologic oncology.

The cost-effectiveness analysis of maintenance olaparib plus Bevacizumab in patients with advanced ovarian cancer: based on the final survival results from PAOLA-1 trial

Hong Zhu, Youwen Zhu, Kun Liu, 2023, Journal of Ovarian Research.

Comparative efficacy and safety of novel immuno-chemotherapy for extensive-stage small-cell lung cancer: a network meta-analysis of randomized controlled trial

Youwen Zhu, Kun Liu, Yangying Zhou, 2023, Therapeutic advances in medical oncology.

Immune checkpoint inhibitor for patients with advanced biliary tract cancer: A cost‐effectiveness analysis

Hong Zhu, Youwen Zhu, Kun Liu, 2023, Liver international : official journal of the International Association for the Study of the Liver.

Adverse events of biologic or small molecule therapies in clinical trials for inflammatory bowel disease: A systematic review and meta-analysis

Youwen Zhu, Kun Liu, Hong Zhu, 2024, Heliyon.

Immunotherapy plus chemotherapy in patients with advanced endometrial cancer: a cost-effectiveness analysis.

Youwen Zhu, Kun Liu, Hong Zhu, 2024, Journal of gynecologic oncology.

Immune checkpoint inhibitors plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer: a cost-effectiveness analysis

Youwen Zhu, Kun Liu, Hong Zhu, 2023, Therapeutic advances in gastroenterology.